In the last trading session, 3.15 million Mainz Biomed N.V. (NASDAQ:MYNZ) shares changed hands as the company’s beta touched 0.09. With the company’s per share price at $0.25 changed hands at $0.04 or 15.47% during last session, the market valuation stood at $5.41M. MYNZ’s last price was a discount, traded about -1256.0% off its 52-week high of $3.39. The share price had its 52-week low at $0.19, which suggests the last value was 24.0% up since then. When we look at Mainz Biomed N.V.’s average trading volume, we note the 10-day average is 2.39 million shares, with the 3-month average coming to 1.72 million.
Mainz Biomed N.V. (NASDAQ:MYNZ) trade information
Instantly MYNZ was in green as seen at the end of in last trading. With action 1.65%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -78.71%, with the 5-day performance at 1.65% in the green. However, in the 30-day time frame, Mainz Biomed N.V. (NASDAQ:MYNZ) is -30.17% down. Looking at the short shares, we see there were 0.72 million shares sold at short interest cover period of 0.39 days.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Mainz Biomed N.V. (MYNZ) estimates and forecasts
Data shows that the Mainz Biomed N.V. share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -76.02% over the past 6 months, a 45.68% in annual growth rate that is considerably higher than the industry average of 17.70%. Year-over-year growth is forecast to reach 34.10% up from the last financial year.
Consensus estimates given by 2 financial analysts project the company’s revenue in the current quarter to hit an average of 220k. 2 analysts are of the opinion that Mainz Biomed N.V.’s revenue for the current quarter will be 300k. The company’s revenue for the corresponding quarters a year ago was 250k. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -12.00%.
MYNZ Dividends
Mainz Biomed N.V. is expected to release its next quarterly earnings report in October.
VONTOBEL HOLDING LTD. holds the second largest percentage of outstanding shares, with 0.1181% or 25000.0 shares worth $10025.0 as of 2024-06-30.
